The ability of bacterial lipopolysaccharides to induce lymphocyte mitogenesis and to act as an adj uvant of antibody formation was attributable to the lipid-A region of the molecule. Measured by induction of DNA synthesis, lipid A was mitogenic for bone marrowderived lymphocytes obtained from spleens of congenitally athymic mice but not for thymocytes obtained from thymuses of normal mice. Adjuvanticity was demonstrated by the ability of lipid A to convert a tolerogenic regimen of antigen into one eliciting an immune response and by its ability to markedly enhance the antibody response to a weak antigen.
Bacterial lipopolysaccharides (LPS) exhibit several biological effects on the immune system. They are mitogenic for lymphocytes, a phenomenon restricted to the bone marrow-derived (B) lymphocyte population (1, 2) , powerful adjuvants of antibody formation (3, 4) , and highly immunogenic in that extremely low concentrations will trigger a specific antibody response in experimental animals (5-7). These three immunologic properties of LPS may be related if the molecule is viewed as a composite of two distinct functional moieties, a site carrying antigenic activity and another site carrying adjuvant activity. The adjuvant activity may in turn derive from the ability of LPS to induce B-cell mitogenesis, an effect whose net result might be to lower the threshold of antigen concentration necessary to stimulate a specific B lymphocyte. The ability of LPS to circumvent thymusderived (T)-cell helper function otherwise required for the initiation of antibody response to T-cell-dependent antigens (8) (9) (10) (11) is compatible with such an interpretation.
The model of LPS as an antigen that carries its own adjuvant was tested by experiments that attempted to correlate the immunologic activities of LPS with its chemical structure. This molecule has been chemically characterized as consisting of three principal regions (12) : (1) the 0 polysaccharide which is linked to (2) the core polysaccharide which is in turn linked to (3) lipid A by a trisaccharide of 2-keto-3-deoxyoctanoic acid. With LPS obtained from different bacterial mutants or components isolated from chemical degradation, it was found that both mitogenicity and adjuvanticity were activities that could be attributed to the lipid region of the molecule, whereas, as described (12) , the major antigenic specificity was correlated with the polysaccharide region.
MATERIALS AND METHODS
Mice. A/J male mice, 5 Preparation of LPS. LPS from E. coli 0111:B4 was extracted from whole cells in aqueous butanol (15) and subsequently fractionated on Sepharose (manuscript in preparation). Briefly, aqueous suspensions of bacteria were treated with butanol-1 at 4°. The aqueous extract of the biphasic system formed by centrifugation at 35,000 X g for 20 min was incubated with Pronase (Calbiochem., La Jolla, Calif.) overnight at 370 and centrifuged (17,000 X g for 10 min), and the supernatant was concentrated by Amicon ultrafiltration. This extract was then fractionated by gel filtration on Sepharose 4B (Pharmacia, Rathway, N.J.) into two wellresolved fractions BI and BII, containing by weight about 1% and 10% lipid A, respectively. These functions are similar in both physical and chemical properties to those obtained when LPS is extracted by the phenol-water procedure of Westphal (16) and fractionated by gel filtration (in preparation). LPS from the mutant strains E. coli 0111: B4, J5, and S. minnesota Re 595 were prepared by the phenol-chloroform-petroleum ether procedure (17) . Commercial preparations of LPS extracted from phenol-water from E. coli 0111:B4 (Lot no. 573564) were obtained from Difco Laboratories (Detroit, Mich.).
Preparation of Lipid A. LPS from E. coli 0111: B4 obtained by the phenol-water procedure (17) and solubilized by addition of triethylamine (18) to a final concentration of 1 g/100 ml. These preparations were shown to be free of detectable 2-keto-3-deoxyoctanoic acid. This criterion has been used by other laboratories to assess the purity of lipid A preparations (19, 20) .
Culture Reagents. Supplemented Minimal Eagle's Medium was prepared as follows: 100 ml contained 89.0 ml of medium, 1.0 ml of 100 X Na pyruvate, 1.0 ml of 100 X nonessential amino acids, 0.1 ml of 100 X glutamine (all from Microbiological Assoc., Albany, Calif.), 3.0 ml of 5.6% NaHCO3 (Flow Laboratories, Inglewood, Calif.), 5.0 ml of fetal-calf serum (Reheis, Chicago, Ill., Lot No. JF6006), and 1.0 ml of 100 X penicillin and streptomycin (final concentration of 100 units/ ml and 100 jug/ml, respectively). Agents used in mitogenesis studies, including LPS and concanavalin A (Miles-Yeda Ltd., Rehovet, Israel), were sterilized by exposure to ultraviolet light.
Lymphocyte Suspensions. The methods used are based on those developed by Mishell and Dutton (21) . Spleens and/or thymuses were removed asceptically from exsanguinated mice and placed in sterile balanced salt solution (22) that contained 100 units of penicillin and 100,ug of streptomycin per ml. Spleen-cell suspensions were prepared by teasing the tissue with mouse-tooth forceps. Thymus-cell suspensions were obtained by grating the glands against a sterile stainless steel screen. Cell clumps and debris were removed by gravity sedimentation for 3 min, after which the supernatants were centrifuged at 225 X g for 10 min. Cell pellets were suspended in 10 ml of supplemented Minimal Eagle's Medium, and the number of viable cells was determined by trypan blue exclusion. Spleen and thymus cells were diluted with supplemented medium to final densities of 2 X 106 and 12 X 106 viable cells per ml, respectively.
Lymphocyte Cultures. Tissue culture dishes (Falcon Plastics, Oxnard, Calif.) were seeded with 1 ml of the appropriate cell suspension and placed in a Lucite box that maintained an atmosphere of 10% C02-7% 02-83% N2. The box was incubated at 370 on a rocker platform (Bellco Glass, Vineland, N.J.) oscillating at 3-4 complete cycles/min. The cultures were each fed daily with four drops of nutritional cocktail (21 mice (23) . Bovine-serum albumin (Lot no. F71703) was purchased from Reheis Laboratories, Chicago, Ill. Enumeration of Antibody-Forming Cells. Cells forming antibody specific to human gammaglobulin, bovine-serum albumin, or lipopolysaccharide were assayed by use of modifications of the Jerne hemolytic plaque assay (24) in which either protein antigens (22) or LPS (6) were coupled to goat erythrocytes (Colorado Serum, Denver, Colo.). Indirect plaque-forming cells (PFC) were developed with antibodies to mouse IgG from squirrel monkey used at a concentration determined to be optimal in the assay.
RESULTS

Mitogenic effect of different LPS preparations
Mitogenic stimulation of spleen cells from nude mice (B cells) was assessed after incubation with LPS of E. coli 0111: B4 either obtained commercially (C-LPS) or extracted by the butanol method and fractionated into two forms, BI-LPS (1% lipid A by weight) and BII-LPS (10% lipid A by weight).
The results obtained are seen in Fig. 1A and reveal that each of the three preparations of LPS tested was mitogenic for B cells. Of the two preparations obtained by butanol extraction and Sepharose fractionation, the one with the lower lipid A concentration (BI-LPS) was markedly less stimulatory. The mitogenic effect of each of the three preparations on thymocytes was negligible, although these cells were readily activated by concanavalin A (Fig. 1B) , a protein previously described to be mitogenic for T cells but not for B cells (2) .
Each of the LPS preparations in contrast was equally immunogenic as tested by the ability to induce a specific antibody response when injected into mice (Table 1) .
Mitogenic effect of LPS with different chemical structures
The above experiment suggested that the mitogenic effect of LPS could be related to a particular structural region of the molecule, namely, the lipid A region. In order to further test this hypothesis, LPS preparations from the following bacteria were tested: (a) from E. coli 011i:B4 (C-LPS), (b) from a galactose epimeraseless mutant of E. coli 0111 : B4, J5 (JS-LPS), and (c) from the heptoseless mutant of S. minnesota, Re 595 (Re 595-LPS). The chemical nature of each of these preparations is depicted in Fig. 2 . In addition, lipid A obtained by mild acid hydrolysis of the LPS from E. coli 0111:B4 was also tested. It was observed that mitogenesis of B cells was induced by each of the preparations of LPS (Fig. 3A) . The activity of the various LPS fractions and of lipid A was restricted to B cells since thymocytes were not stimulated (Fig. 3B ). In contrast, concanavaiin A was stimulatory to thymocytes ( Fig. 3B ) but not to B cells (Fig. 3A) . Not 
Adjuvanticity of LPS preparations
Two procedures were used to determine whether the various LPS preparations and lipid A had in vivo activity as adjuvants of antibody formation.
(a) Response to bovine-serum albumin: A/J male mice (9 weeks of age) were injected intravenously with 500 Jug of bovine-serum albumin. 3 Hr later, they received another intra- 14 Days later, all groups were injected with 200 /Ag of soluble bovine-serum albumin given intraperitoneally, and the number of plaque-forming cells specific to bovine-serum albumin was quantitated in the spleens of these animals at various times after the last antigenic challenge. The results of this experiment are shown in Table 2 and clearly reveal that the potent adjuvant effect of LPS can be attributed to those preparations of LPS that contain lipid A. Thus, LPS obtained from the S. Minnesota mutant Re 595, which structurally contains only lipid A and a trisaccharide of 2-beta-3-deoxy-octanoic acid, displays adjuvanticity. In contrast, neither the capsular polysaccharide of pneumococcus nor concanavalin A markedly enhance the response to bovineserum albumin.
(b) Conversion of tolerance to immunity: It has been recently observed that LPS treatment after injection of deaggregated IgG can convert this usually tolerogenic regimen to an immune response specific to human gammaglobulin (manuscript in preparation). Since this phenomenon may be regarded as a stringent definition of an adjuvant effect, it was used as a system to provide another index of the adjuvant activity of the various LPS preparations and of lipid A. A/5 male mice, 6 weeks of age, were injected intraperitoneally with 2.5 mg of deaggregated IgG given in a 1-ml volume. 3 Hr later, they were given an intravenous injection of saline or 50 ug of C-LPS, BII-LPS, J5-LPS, Re 595-LPS, or lipid A. From the data presented in Table 3 , we conclude that the effect of converting a tolerogenic injection of deaggregated IgG to a specific antibody response to that antigen is a function that can also be attributed to the lipid A portion of the LPS molecule.
DISCUSSION
The ability of LPS to act as a mitogen for B lymphocytes and as an adjuvant for antibody formation are properties that the present data show to be attributable to the lipid A portion of the LPS molecule. The fact that there exists a close parallelism in structure-function relationship between mitogenic stimulation on one hand and adjuvant activity on the other suggests that these two phenomena may be related. The mode of action of LPS as an adjuvant could be viewed as the result of the induction of B-cell mitogenesis mediated by its lipid A, an effect that would lower the amount of antigen necessary for specific B-cell stimulation. A similar mechanism has been proposed to explain the mode of action of the helper function of T cells in the observed T cell-B cell cooperation in antibody formation (25) . The ability of LPS to bypass the requirement of T-cell help has been demonstrated in several studies (8) (9) (10) (11) and provides an observation compatible with the present interpretation. However, the adjuvant effect of LPS may be mediated other than by its mitogenic action on B cells. Alternatives that could be considered include interference with a feedback mechanism operative in antibody formation (26) , toxicity, causing the release of cellular breakdown products such as nucleotides which are themselves adjuvants (27) , or the alteration of intracellular processing events that operate in the reticuloendothelial limb of the immune response (28) .
The present data offer an insight into a structural relationship between the adjuvant property of LPS and its potent immunogenicity when injected into experimental animals. As first shown by Landy and Baker (5), a specific immune response (PFC) can be observed in the popliteal lymph nodes of rabbits after a footpad injection of a few thousand molecules of LPS from S. enteritidis. The observation that a few molecules could immunologically sensitize mice to LPS from E. coli also led Rudbach to conclude that this preparation is in fact a "super antigen" (6). Nossal and Ada (7) Proc. Nat. Acad. Sci. USA 70 (1973) (wow).
